Corona Remedies Ltd Share Price

Q: What is the share price of Corona Remedies Ltd today?

Corona Remedies Ltd share price as on 12 Jun 2026 is ₹1702.1

Pharmaceuticals

NSE: CORONA Small Cap ISIN: INE02ZQ01018

As on 13 June 2026 at 02:35 IST

₹1,702.10

+ 18.90

(1.12%)

Sell Buy

Over 1 Month

-4.13%

Over 6 Months

17.02%

Over 1 Year

None%

Over 3 Years

None%

Corona Remedies Ltd Summary

Close ₹1,683.20

Open ₹1,680

High ₹1,745

Low ₹1,658.10

Volume 73,152

Net Turnover (in Cr) ₹12.36

52Wk High ₹1,949.40

52Wk Low ₹1,336.60

52Wk High / Low

1,336.60

1,949.40

Corona Remedies Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹10,294.47

EPS (TTM) 32.63

Book Value (BV) 121.97

Div. Yield 0.59 %

P/E (TTM) 55.62

Price/Book Value 13.78

Delivery % 57.32 %

Face Value 10

Key Ratios

PE Ratio -

PB Ratio -

EV to Sales -

PEG Ratio -

ROA 20.40

ROE 27.45

Debt-Equity 0.23

Net Profit Margin 12.46

Operating Profit Margin 20.55

Corona Remedies Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023
Total Revenue	1,202.35	1,020.93	891.10
Total Expenses	1,004.21	902.46	780.44
Profit Before Tax	198.53	118.48	110.89
Profit After Tax	149.43	90.50	84.93
Operating Profit After Depreciation	208.75	132.91	114.93

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023
Fixed Assets	369.88	383.70	184.59
Total Non Current Assets	590.99	540.66	303.54
Total Current Assets	338.87	289.92	291.49
Total Assets	929.86	830.58	595.02
Total Shareholder's Fund	606.34	480.41	408.52

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023
Net Cash From Operating Activities	190.50	156.76	102.70
Net Cash Used In Investing Activities	-83.84	-266.64	-50.28
Net Cash Used In Financing Activities	-106.59	98.55	-44.75

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020
Total Revenue	1,202.35	1,020.93	891.10	623.93	605.48
Total Expenses	1,004.21	902.46	780.44	624.72	527.13
Profit Before Tax	198.15	118.48	110.66	-0.79	78.35
Profit After Tax	149.05	90.50	84.70	-0.40	59.40
Operating Profit After Depreciation	208.75	132.91	114.93	3.93	79.41

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020
Fixed Assets	369.88	383.70	184.59	161.76	68.80
Total Non Current Assets	590.37	540.42	303.31	227.75	145.93
Total Current Assets	338.87	289.92	291.49	283.61	250.38
Total Assets	929.24	830.34	594.80	511.36	396.32
Total Shareholder's Fund	605.73	480.18	408.29	320.91	269.15

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	190.49	156.76	102.70	97.70	79.16
Net Cash Used In Investing Activities	-83.84	-266.64	-50.28	-65.81	-102.12
Net Cash Used In Financing Activities	-106.59	98.54	-44.75	-29.86	0.09

Particulars (in ₹ Cr.)	2026-03	2025-12	2025-09	2025-06	2025-03
Total Revenue	353.09	342.42	361.13	346.54	293.69
Total Expenses	291.07	259.26	282.66	276.96	239.47
Profit Before Tax	54.74	55.21	69.78	60.69	43.61
Profit After Tax	45.33	41.27	52.32	46.20	31.55
Operating Profit after Depreciation	66.41	85.42	80.91	71.60	55.85

Particulars (in ₹ Cr.)	2026-03	2025-12	2025-09	2025-06	2025-03
Total Revenue	353.09	342.42	361.13	346.54	293.69
Total Expenses	291.07	259.26	282.66	276.76	239.47
Profit Before Tax	54.46	55.19	69.61	60.89	43.40
Profit After Tax	45.05	41.25	52.15	46.40	31.34
Operating Profit after Depreciation	66.13	85.40	80.74	71.80	55.64

Corona Remedies Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,645.87

S2 1,608.53

S3 1,558.97

Pivot 1,695.43

R1 1,732.77

R2 1,782.33

R3 1,819.67

Moving Average

20 SMA 1,723.76

50 SMA 1,669.67

100 SMA 1,606.36

200 SMA -

Corona Remedies Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,794.30	₹4,30,512.67
Divis Laboratories Ltd	₹6,651.25	₹1,76,569.79
Torrent Pharmaceuticals Ltd	₹4,570	₹1,54,669.57
Cipla Ltd	₹1,383	₹1,11,725.01
Zydus Lifesciences Ltd	₹1,105.65	₹1,11,254.26

Corona Remedies Ltd Top Mutal Funds Invested

Fund Name	AUM
Aditya Birla SL Pharma & Healthcare Fund	2.06%
Invesco India Smallcap Fund	2%
Edelweiss Recently Listed IPO Fund	1.84%
Invesco India Multicap Fund	1.15%
WhiteOak Capital Special Opportunities Fund	1.14%

Corona Remedies Ltd News

Board of Corona Remedies recommends final dividend

Of Rs 10 per share

12 May 2026, 09:21 am

Corona Remedies to discuss results

On 11 May 2026

02 May 2026, 10:56 am

Corona Remedies acquires Wokadine from DR Reddy's Laboratories

Corona Remedies announced the acquisition of Wokadine brand from Dr. Reddy's Laboratories to strengthen its presence in targeted specialty segment and offer wider accessibility.

31 Mar 2026, 09:45 am

Corona Remedies to hold board meeting

On 2 February 2026

28 Jan 2026, 11:03 am

Corona Remedies gains as Q2 PAT climbs 22% YoY to Rs 52 cr

Corona Remedies added 1.19% to Rs 1,462.95 after it has reported 21.75% increase in consolidated net profit to Rs 52.32 crore on 15.05% rise in revenue from operations to Rs 361.13 crore in Q2 FY26 over Q2 FY25.

05 Jan 2026, 09:41 am

Corona Remedies Ltd Stock Analysis

Annual revenue for Corona Remedies Ltd increased by 17.77% to ₹1,202.35 crore in FY 2025 from ₹1,020.93 crore in FY 2024.
Annual Net Profit for Corona Remedies Ltd increased by 64.70% to ₹149.05 crore in FY 2025 from ₹90.50 crore in FY 2024.
Promoter Shareholding in Corona Remedies Ltd remains unchanged by 0.00% in the most recent quarter, from 69% in December 2025 to 69% in March 2026.
Corona Remedies Ltd delivered a 1-year return of 0% compared to the Nifty 50, which provided a return of -7.87% as of the last trading session.
Corona Remedies Ltd share price moved up by 1.12% from its previous close of INR ₹1,683.20. The latest Corona Remedies Ltd share price is INR ₹1,702.10.
Corona Remedies Ltd share price today has been at a low of 1,694 and a high of 1,715.10. Over the past 52 weeks, the Corona Remedies Ltd share price has seen a low of 1,336.60 and a high of 1,949.40.